PERRIGO COMPANY PLC PERRIGO FINANCE PLC

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "PERRIGO COMPANY PLC PERRIGO FINANCE PLC"

Transcription

1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 24, 2014 PERRIGO COMPANY PLC PERRIGO FINANCE PLC (Exact name of registrant as specified in its charter) Commission file number Ireland (State or other jurisdiction of incorporation or organization) Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland (Address of principal executive offices) Not Applicable (I.R.S. Employer Identification No.) Not Applicable (Zip Code) (Registrant s telephone number, including area code) Not Applicable (Former name, former address and former fiscal year, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR ) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR e-4(c))

2 Item 8.01 Other Events. Existing Notes Guarantees Release Each of the guarantors under the Indenture (the Indenture ), dated as of November 8, 2013, among Perrigo Company plc (the Company ), the guarantors party thereto and Wells Fargo Bank, National Association, as Trustee, have been released of their guarantees and have no further liability or obligations pursuant to Section 1712 of the Indenture and upon the release by the banks of their guarantee, as of November 21, Equity Offering Greenshoe Exercise On November 24, 2014, the Company issued a press release announcing that the underwriters for the Company s public equity offering of 5,921,053 ordinary shares announced in its Current Report on Form 8-K, filed on November 20, 2014, exercised their option, in full, to purchase an additional 888,157 ordinary shares of the Company at $ per share, less the underwriting discount. The press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference. New Notes Offering Launch On November 24, 2014, the Company issued a press release announcing that Perrigo Finance plc, a finance subsidiary of the Company incorporated under the laws of Ireland (the Issuer ), commenced a registered public offering of three series of Senior Notes (collectively, the New Notes ). The New Notes will be fully and unconditionally guaranteed on a senior unsecured basis by the Company. The exact terms and timing of the offering will depend upon market conditions and other factors. A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference. The Company intends to use the net proceeds of the New Notes offering to fund a portion of the cash consideration for its proposed acquisition (the Acquisition ) of Omega Pharma Invest NV ( Omega ), as previously disclosed in the Company s Current Report on Form-8-K filed with the Securities and Exchange Commission (the SEC ) on November 6, The New Notes offering is not contingent on the consummation of the Acquisition. If the Acquisition is not consummated for any reason, the proceeds from the New Notes offering will be used to redeem the notes at a redemption price of 101% of the aggregate principal amount of the notes, plus accrued and unpaid interest to, but not including, the redemption date. The New Notes offering is expected to close prior to the consummation of the Acquisition. In connection with the New Notes offering, the Company expects to file with the SEC a preliminary prospectus supplement dated November 24, 2014 pursuant to the Company s shelf registration statement on Form S-3, which became effective on November 20, Item 9.01 (d) Exhibits Financial Statements and Exhibits. Exhibit 99.1 Press release issued by Perrigo Company plc on November 24, Exhibit 99.2 Press release issued by Perrigo Company plc on November 24, No Offer or Solicitation This Form 8-K does not constitute an offer to sell, or an invitation to subscribe for, purchase or exchange, any securities, nor shall there be any sale, issuance, exchange or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law. Cautionary Statement Regarding Forward-Looking Statements This Form 8-K includes certain forward looking statements within the meaning of, and subject to the safe harbor created by, Section 21E of the Securities Exchange Act of 1934, as amended, with respect to the business, strategy and plans of the Company, its expectations and its future financial condition and performance. Statements that are

3 not historical facts, including statements about the Company s managements beliefs and expectations, are forward looking statements. Words such as may, will, could, would, should, expect, plan, anticipate, intend, believe, estimate, predict, potential or the negative of those terms or other comparable terminology are intended to identify forward looking statements but are not the exclusive means of identifying such statements. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company s control. By their nature, forward looking statements involve risk and uncertainty because they relate to events and depend upon future circumstances that may or may not occur. Actual results may differ materially from the Company s current expectations depending upon a number of factors affecting the Company s business. These factors include, among others, the inherent uncertainty associated with financial projections; successful completion of the transactions contemplated herein; the risks and uncertainties normally incident to the pharmaceutical industry, including product liability claims and the availability of product liability insurance; market acceptance of and continued demand for the Company s products; changes in tax laws or interpretations that could increase the Company s tax liabilities; and such other risks and uncertainties detailed in the Company s periodic public filings with the SEC, including but not limited to those discussed under Risk Factors in the Company s Form 10-K for the fiscal year ended June 28, 2014, in the subsequent filings with the SEC and in other investor communications of the Company from time to time. The forward-looking statements in this document are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

4 Signature Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: November 24, 2014 PERRIGO COMPANY PLC (Registrant) By: /s/ Judy L. Brown Judy L. Brown Executive Vice President and Chief Financial Officer (Principal Accounting and Financial Officer) PERRIGO FINANCE PLC (Registrant) By: /s/ Todd W. Kingma Todd W. Kingma Secretary (Principal Officer)

5 Exhibit Index Exhibit 99.1 Press release issued by Perrigo Company plc on November 24, Exhibit 99.2 Press release issued by Perrigo Company plc on November 24, 2014.

6 Exhibit 99.1 PERRIGO COMPANY PLC ANNOUNCES UNDERWRITERS FULL EXERCISE OF OPTION TO PURCHASE ORDINARY SHARES IN CONNECTION WITH THE EQUITY OFFERING Dublin, Ireland (November 24, 2014) Perrigo Company plc ( Perrigo ) (NYSE: PRGO; TASE), a leading global provider of Quality Affordable Healthcare Products, today announced that the underwriters for Perrigo s previously announced public equity offering of 5,921,053 ordinary shares exercised their option, in full, to purchase an additional 888,157 ordinary shares of Perrigo at $ per share, less the underwriting discount (collectively, the Equity Offering ). Perrigo estimates that the net proceeds from the full exercise of the option will be approximately $135 million and that the total net proceeds of the Equity Offering will be approximately $1.0 billion. Perrigo intends to use the net proceeds of the Equity Offering, together with the proceeds of other financing sources, to fund the cash consideration for its proposed acquisition (the Acquisition ) of Omega Pharma Invest NV ( Omega ) and to repay or refinance certain indebtedness of Perrigo and/or Omega. The Equity Offering is not contingent on the consummation of the Acquisition. If the Acquisition is not consummated, then the net proceeds of the Equity Offering will be used for general corporate purposes, which may include capital expenditures; the repayment of debt; investments in subsidiaries; additions to working capital; the repurchase, redemption or retirement of our securities; acquisitions and other business opportunities. The Equity Offering is expected to close on November 26, 2014, which is prior to the expected date of the consummation of the Acquisition. J.P. Morgan, Barclays and BofA Merrill Lynch acted as the joint book-running managers in the offering. The offering is being made pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission ( SEC ). The offering will be made only by means of a prospectus supplement relating to the offering and the accompanying base prospectus, copies of which may be obtained by contacting: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: (866) ; or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or telephone: (888) About Perrigo From its beginnings as a packager of generic home remedies in 1887, Perrigo Company plc, headquartered in Ireland, has grown to become a leading global healthcare supplier. Perrigo develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products and active pharmaceutical ingredients (API), and receives royalties from Multiple Sclerosis drug Tysabri. The Company is the world s largest manufacturer of OTC healthcare products for the store brand market and an industry leader in pharmaceutical technologies. Perrigo s mission is to offer uncompromised Quality Affordable Healthcare Products and it does so across a wide variety of product categories primarily in the United States, United Kingdom, Mexico, Israel and Australia, as well as more than 40 other key markets worldwide, including Canada, China and Latin America. For more information: Arthur J. Shannon, Vice President, Investor Relations and Global Communications, (269) , or Bradley Joseph, Director, Investor Relations and Global Communications, (269) ,

7 No Offer or Solicitation This press release does not constitute an offer to sell, or an invitation to subscribe for, purchase or exchange, any securities, nor shall there be any sale, issuance, exchange or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law. Cautionary Statement Regarding Forward-Looking Statements This press release includes certain forward looking statements within the meaning of, and subject to the safe harbor created by, Section 21E of the Securities Exchange Act of 1934, as amended, with respect to the business, strategy and plans of the Company, its expectations and its future financial condition and performance. Statements that are not historical facts, including statements about the Company s managements beliefs and expectations, are forward looking statements. Words such as may, will, could, would, should, expect, plan, anticipate, intend, believe, estimate, predict, potential or the negative of those terms or other comparable terminology are intended to identify forward looking statements but are not the exclusive means of identifying such statements. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forwardlooking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company s control. By their nature, forward looking statements involve risk and uncertainty because they relate to events and depend upon future circumstances that may or may not occur. Actual results may differ materially from the Company s current expectations depending upon a number of factors affecting the Company s business. These factors include, among others, the inherent uncertainty associated with financial projections; successful completion of the transactions contemplated herein; the risks and uncertainties normally incident to the pharmaceutical industry, including product liability claims and the availability of product liability insurance; market acceptance of and continued demand for the Company s products; changes in tax laws or interpretations that could increase the Company s tax liabilities; and such other risks and uncertainties detailed in the Company s periodic public filings with the SEC, including but not limited to those discussed under Risk Factors in the Company s Form 10-K for the fiscal year ended June 28, 2014, in the subsequent filings with the SEC and in other investor communications of the Company from time to time. The forwardlooking statements in this document are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

8 Exhibit 99.2 PERRIGO COMPANY PLC ANNOUNCES PROPOSED PUBLIC OFFERING OF SENIOR NOTES OF ITS FINANCE SUBSIDIARY, PERRIGO FINANCE PLC Dublin, Ireland (November 24, 2014) Perrigo Company plc ( Perrigo ) (NYSE: PRGO; TASE), a leading global provider of Quality Affordable Healthcare Products, today announced that Perrigo Finance plc, a finance subsidiary of Perrigo incorporated under the laws of Ireland (the Issuer ), commenced a registered public offering of three series of Senior Notes (collectively, the Notes ). The Notes will be fully and unconditionally guaranteed on a senior unsecured basis by the Company. The exact terms and timing of the offering will depend upon market conditions and other factors. Perrigo intends to use the net proceeds of the offering, together with the proceeds of other financing sources, to fund the cash consideration for its proposed acquisition (the Acquisition ) of Omega Pharma Invest NV ( Omega ) and to repay or refinance certain indebtedness of Perrigo and/or Omega. The offering is not contingent on the consummation of the Acquisition. If the Acquisition is not consummated for any reason, the proceeds from the offering will be used to redeem the notes at a redemption price of 101% of the aggregate principal amount of the notes, plus accrued and unpaid interest to, but not including, the redemption date. The offering is expected to close prior to the consummation of the Acquisition. J.P. Morgan, Barclays, BofA Merrill Lynch, HSBC and Wells Fargo Securities are the joint book-running managers in the offering. The offering is being made pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission ( SEC ). The offering will be made only by means of a prospectus supplement relating to the offering and the accompanying base prospectus, copies of which may be obtained by contacting: J.P. Morgan Securities LLC, 383 Madison Avenue, New York, NY 10179, Attn: Investment Grade Syndicate Desk, telephone: (212) ; or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or telephone: (888) About Perrigo From its beginnings as a packager of generic home remedies in 1887, Perrigo Company plc, headquartered in Ireland, has grown to become a leading global healthcare supplier. Perrigo develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products and active pharmaceutical ingredients (API), and receives royalties from Multiple Sclerosis drug Tysabri. The Company is the world s largest manufacturer of OTC healthcare products for the store brand market and an industry leader in pharmaceutical technologies. Perrigo s mission is to offer uncompromised Quality Affordable Healthcare Products and it does so across a wide variety of product categories primarily in the United States, United Kingdom, Mexico, Israel and Australia, as well as more than 40 other key markets worldwide, including Canada, China and Latin America. For more information: Arthur J. Shannon, Vice President, Investor Relations and Global Communications, (269) , or Bradley Joseph, Director, Investor Relations and Global Communications, (269) ,

9 No Offer or Solicitation This press release does not constitute an offer to sell, or an invitation to subscribe for, purchase or exchange, any securities, nor shall there be any sale, issuance, exchange or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law. Cautionary Statement Regarding Forward-Looking Statements This press release includes certain forward looking statements within the meaning of, and subject to the safe harbor created by, Section 21E of the Securities Exchange Act of 1934, as amended, with respect to the business, strategy and plans of the Company, its expectations and its future financial condition and performance. Statements that are not historical facts, including statements about the Company s managements beliefs and expectations, are forward looking statements. Words such as may, will, could, would, should, expect, plan, anticipate, intend, believe, estimate, predict, potential or the negative of those terms or other comparable terminology are intended to identify forward looking statements but are not the exclusive means of identifying such statements. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forwardlooking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company s control. By their nature, forward looking statements involve risk and uncertainty because they relate to events and depend upon future circumstances that may or may not occur. Actual results may differ materially from the Company s current expectations depending upon a number of factors affecting the Company s business. These factors include, among others, the inherent uncertainty associated with financial projections; successful completion of the transactions contemplated herein; the risks and uncertainties normally incident to the pharmaceutical industry, including product liability claims and the availability of product liability insurance; market acceptance of and continued demand for the Company s products; changes in tax laws or interpretations that could increase the Company s tax liabilities; and such other risks and uncertainties detailed in the Company s periodic public filings with the SEC, including but not limited to those discussed under Risk Factors in the Company s Form 10-K for the fiscal year ended June 28, 2014, in the subsequent filings with the SEC and in other investor communications of the Company from time to time. The forwardlooking statements in this document are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

P. H. Glatfelter Company (Exact name of registrant as specified in its charter)

P. H. Glatfelter Company (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event

More information

IHEARTMEDIA CAPITAL I, LLC

IHEARTMEDIA CAPITAL I, LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

FEDERAL DEPOSIT INSURANCE CORPORATION Washington, D.C. 20429 FORM 8-K. Summit State Bank (Exact name of registrant as specified in its charter)

FEDERAL DEPOSIT INSURANCE CORPORATION Washington, D.C. 20429 FORM 8-K. Summit State Bank (Exact name of registrant as specified in its charter) FEDERAL DEPOSIT INSURANCE CORPORATION Washington, D.C. 20429 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported):

More information

INTERNATIONAL BANCSHARES CORPORATION (Exact Name of registrant as specified in its charter)

INTERNATIONAL BANCSHARES CORPORATION (Exact Name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest

More information

INCONTACT, INC. FORM 8-K. (Current report filing) Filed 03/25/15 for the Period Ending 03/23/15

INCONTACT, INC. FORM 8-K. (Current report filing) Filed 03/25/15 for the Period Ending 03/23/15 INCONTACT, INC. FORM 8-K (Current report filing) Filed 03/25/15 for the Period Ending 03/23/15 Address 7730 S. UNION PARK AVE., SUITE 500 NONE MIDVALE, UT 84047 Telephone (801) 320-3300 CIK 0001087934

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

FORM 8-K. DUKE ENERGY CAROLINAS, LLC (Exact Name of Registrant as Specified in its Charter)

FORM 8-K. DUKE ENERGY CAROLINAS, LLC (Exact Name of Registrant as Specified in its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 31, 2007 (Date

More information

HOME LOAN SERVICING SOLUTIONS, LTD.

HOME LOAN SERVICING SOLUTIONS, LTD. HOME LOAN SERVICING SOLUTIONS, LTD. FORM DEFA14A (Additional Proxy Soliciting Materials (definitive)) Filed 04/24/15 Telephone (345) 945-3727 CIK 0001513161 Symbol HLSS SIC Code 6162 - Mortgage Bankers

More information

SECURITIES AND EXCHANGE COMMISSION FORM 8-K. Current report filing

SECURITIES AND EXCHANGE COMMISSION FORM 8-K. Current report filing SECURITIES AND EXCHANGE COMMISSION FORM 8-K Current report filing Filing Date: 2005-11-07 Period of Report: 2005-11-01 SEC Accession No. 0000950137-05-013397 (HTML Version on secdatabase.com) FILER PRINCIPAL

More information

FEDERAL DEPOSIT INSURANCE CORPORATION. Washington, D.C FORM 8-K CURRENT REPORT. PURSUANT TO SECTION 13 OR 15(d)

FEDERAL DEPOSIT INSURANCE CORPORATION. Washington, D.C FORM 8-K CURRENT REPORT. PURSUANT TO SECTION 13 OR 15(d) FEDERAL DEPOSIT INSURANCE CORPORATION Washington, D.C. 20429 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported):

More information

JER INVESTORS TRUST INC (JERT) 8-K. Current report filing Filed on 04/11/2007 Filed Period 04/11/2007

JER INVESTORS TRUST INC (JERT) 8-K. Current report filing Filed on 04/11/2007 Filed Period 04/11/2007 JER INVESTORS TRUST INC (JERT) 8-K Current report filing Filed on 04/11/2007 Filed Period 04/11/2007 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant

More information

NEWS CORP FORM 8-K. (Current report filing) Filed 01/15/16 for the Period Ending 01/15/16

NEWS CORP FORM 8-K. (Current report filing) Filed 01/15/16 for the Period Ending 01/15/16 NEWS CORP FORM 8-K (Current report filing) Filed 01/15/16 for the Period Ending 01/15/16 Address 1211 AVENUE OF THE AMERICAS NEW YORK, NY 10036 Telephone 212-416-3400 CIK 0001564708 Symbol NWS SIC Code

More information

FEDERAL DEPOSIT INSURANCE CORPORATION. Washington, D.C. 20429 FORM 8-K CURRENT REPORT. PURSUANT TO SECTION 13 OR 15(d)

FEDERAL DEPOSIT INSURANCE CORPORATION. Washington, D.C. 20429 FORM 8-K CURRENT REPORT. PURSUANT TO SECTION 13 OR 15(d) FEDERAL DEPOSIT INSURANCE CORPORATION Washington, D.C. 20429 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported):

More information

UNITED STATES. SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K

UNITED STATES. SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

JER INVESTORS TRUST INC (JERT) 8-K. Current report filing Filed on 01/29/2009 Filed Period 01/28/2009

JER INVESTORS TRUST INC (JERT) 8-K. Current report filing Filed on 01/29/2009 Filed Period 01/28/2009 JER INVESTORS TRUST INC (JERT) 8-K Current report filing Filed on 01/29/2009 Filed Period 01/28/2009 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant

More information

DAG MEDIA INC. FORM 8-K/A (Unscheduled Material Events) Filed 6/28/2006 For Period Ending 4/20/2006

DAG MEDIA INC. FORM 8-K/A (Unscheduled Material Events) Filed 6/28/2006 For Period Ending 4/20/2006 DAG MEDIA INC FORM 8-K/A (Unscheduled Material Events) Filed 6/28/2006 For Period Ending 4/20/2006 Address 125 QUEENS BLVD STE 14 KEW GARDENS, New York 11415 CIK 0001080340 Industry Printing & Publishing

More information

LMI AEROSPACE INC FORM 8-K. (Current report filing) Filed 05/09/16 for the Period Ending 05/09/16

LMI AEROSPACE INC FORM 8-K. (Current report filing) Filed 05/09/16 for the Period Ending 05/09/16 LMI AEROSPACE INC FORM 8-K (Current report filing) Filed 05/09/16 for the Period Ending 05/09/16 Address 411 FOUNTAIN LAKES BLVD. ST CHARLES, MO 63301 Telephone 636-946-6525 CIK 0001059562 Symbol LMIA

More information

COSTCO WHOLESALE CORPORATION (Exact name of registrant as specified in its charter)

COSTCO WHOLESALE CORPORATION (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event

More information

AMERUS GROUP CO/IA. FORM 8-K (Current report filing) Filed 8/15/2006 For Period Ending 8/14/2006

AMERUS GROUP CO/IA. FORM 8-K (Current report filing) Filed 8/15/2006 For Period Ending 8/14/2006 AMERUS GROUP CO/IA FORM 8-K (Current report filing) Filed 8/15/2006 For Period Ending 8/14/2006 Address 699 WALNUT STREET DES MOINES, Iowa 50309 Telephone 515-362-3600 CIK 0001051717 Industry Insurance

More information

igo, Inc. (Exact name of registrant as specified in its charter)

igo, Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 8-K ABBVIE INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 8-K ABBVIE INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

CERIDIAN CORPORATION

CERIDIAN CORPORATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

IMS HEALTH HOLDINGS, INC.

IMS HEALTH HOLDINGS, INC. IMS HEALTH HOLDINGS, INC. FORM 8-K (Current report filing) Filed 06/30/14 for the Period Ending 06/30/14 Address 83 WOOSTER HEIGHTS ROAD DANBURY, CT 06810 Telephone 203-448-4600 CIK 0001595262 Symbol IMS

More information

IMPERIAL HOLDINGS, INC.

IMPERIAL HOLDINGS, INC. IMPERIAL HOLDINGS, INC. FORM 8-K (Current report filing) Filed 01/03/12 for the Period Ending 12/30/11 Address 701 PARK OF COMMERCE BOULEVARD SUITE 301 BOCA RATON, FL 33487 Telephone 561-995-4200 CIK 0001494448

More information

Ladenburg Thalmann Financial Services Inc.

Ladenburg Thalmann Financial Services Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event

More information

Washington, D.C CONTINENTAL AIRLINES, INC. (Exact name of registrant as specified in its charter)

Washington, D.C CONTINENTAL AIRLINES, INC. (Exact name of registrant as specified in its charter) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):

More information

JACOBS ENGINEERING GROUP INC /DE/

JACOBS ENGINEERING GROUP INC /DE/ JACOBS ENGINEERING GROUP INC /DE/ FORM 8-K (Current report filing) Filed 04/29/14 for the Period Ending 04/28/14 Address 155 NORTH LAKE AVENUE PASADENA, CA 91101 Telephone 6265783500 CIK 0000052988 Symbol

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

TECO ENERGY INC FORM 8-K. (Current report filing) Filed 09/03/14 for the Period Ending 09/02/14

TECO ENERGY INC FORM 8-K. (Current report filing) Filed 09/03/14 for the Period Ending 09/02/14 TECO ENERGY INC FORM 8-K (Current report filing) Filed 09/03/14 for the Period Ending 09/02/14 Address 702 N FRANKLIN ST TECO PLAZA TAMPA, FL 33602 Telephone 8132284111 CIK 0000350563 Symbol TE SIC Code

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 8, 2014 Date of Report (Date of

More information

FORM 8-K. CREATIVE REALITIES, INC. (Exact name of registrant as specified in its charter)

FORM 8-K. CREATIVE REALITIES, INC. (Exact name of registrant as specified in its charter) 8-K 1 f8k091514_creativerealities.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE

More information

Morningstar Document Research

Morningstar Document Research Morningstar Document Research FORM8-K PAYCHEX INC - PAYX Filed: March 25, 2015 (period: March 25, 2015) Report of unscheduled material events or corporate changes. The information contained herein may

More information

15, April 15, July 15 and October 15 of each year, commencing on April 15, 2015 and ending on, and including, January 15, 2018.

15, April 15, July 15 and October 15 of each year, commencing on April 15, 2015 and ending on, and including, January 15, 2018. NEWS RELEASE SOUTHWESTERN ENERGY PRICES UPSIZED OFFERINGS OF 26,086,957 SHARES OF COMMON STOCK AND 30,000,000 DEPOSITARY SHARES REPRESENTING INTERESTS IN MANDATORY CONVERTIBLE PREFERRED STOCK Spring, Texas

More information

SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K CURRENT REPORT. Date of Report (Date of earliest event reported): May 5, 2016

SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K CURRENT REPORT. Date of Report (Date of earliest event reported): May 5, 2016 IPCC 8-K 5/5/2016 Section 1: 8-K (8-K) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

HORIZON PHARMA PLC FORM 8-K. (Current report filing) Filed 05/19/16 for the Period Ending 05/18/16

HORIZON PHARMA PLC FORM 8-K. (Current report filing) Filed 05/19/16 for the Period Ending 05/18/16 HORIZON PHARMA PLC FORM 8-K (Current report filing) Filed 05/19/16 for the Period Ending 05/18/16 Telephone 011-353-1-772-2100 CIK 0001492426 Symbol HZNP SIC Code 2834 - Pharmaceutical Preparations Industry

More information

Healthcare Trust of America, Inc.

Healthcare Trust of America, Inc. Page 1 of 5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of

More information

Zilog, Inc. (Exact name of registrant as specified in its charter)

Zilog, Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

National American University Holdings, Inc.

National American University Holdings, Inc. SECURITIES & EXCHANGE COMMISSION EDGAR FILING National American University Holdings, Inc. Form: 8-K Date Filed: 2015-08-13 Corporate Issuer CIK: 1399855 Copyright 2015, Issuer Direct Corporation. All Right

More information

EXPEDIA, INC. FORM 8-K. (Current report filing) Filed 11/14/14 for the Period Ending 11/13/14

EXPEDIA, INC. FORM 8-K. (Current report filing) Filed 11/14/14 for the Period Ending 11/13/14 EXPEDIA, INC. FORM 8-K (Current report filing) Filed 11/14/14 for the Period Ending 11/13/14 Address 333 108TH AVENUE NE BELLEVUE, WA 98004 Telephone (425) 679-7200 CIK 0001324424 Symbol EXPE SIC Code

More information

GLOBAL DEFENSE & NATIONAL SECURITY SYSTEMS, INC.

GLOBAL DEFENSE & NATIONAL SECURITY SYSTEMS, INC. GLOBAL DEFENSE & NATIONAL SECURITY SYSTEMS, INC. FORM DEFA14A (Additional Proxy Soliciting Materials (definitive)) Filed 07/14/15 Address 11921 FREEDOM DRIVE, SUITE 550 TWO FOUNTAIN SQUARE RESTON, VA 20190

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

IDEXX LABORATORIES, INC.

IDEXX LABORATORIES, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event

More information

AZTECA ACQUISITION CORP

AZTECA ACQUISITION CORP AZTECA ACQUISITION CORP FORM 8-K (Current report filing) Filed 03/19/13 for the Period Ending 03/18/13 Address 421 N BEVERLY DRIVE SUITE 300 BEVERLY HILLS, CA 90210 Telephone 3105537009 CIK 0001518749

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

DELTA TUCKER HOLDINGS, INC.

DELTA TUCKER HOLDINGS, INC. DELTA TUCKER HOLDINGS, INC. FORM 8-K (Current report filing) Filed 10/30/14 for the Period Ending 10/30/14 Address 13601 NORTH FREEWAY, SUITE 200 FORT WORTH, TX 76177 Telephone 571-722-0210 CIK 0001514226

More information

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported):

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 8-K/A. Vanguard Natural Resources, LLC (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 8-K/A. Vanguard Natural Resources, LLC (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest

More information

Form 8-K. Current Report. Caterpillar Financial Services Corporation

Form 8-K. Current Report. Caterpillar Financial Services Corporation UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

Victory Energy Corporation (Exact name of registrant as specified in its charter)

Victory Energy Corporation (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

FORM 8-K SPDR GOLD TRUST SPONSORED BY WORLD GOLD TRUST SERVICES, LLC

FORM 8-K SPDR GOLD TRUST SPONSORED BY WORLD GOLD TRUST SERVICES, LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

Delaware 000-50703 14-1839426 (State or other jurisdiction of incorporation)

Delaware 000-50703 14-1839426 (State or other jurisdiction of incorporation) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 7, 2014 (Date

More information

AMERICAN EXPRESS COMPANY (Exact name of registrant as specified in its charter)

AMERICAN EXPRESS COMPANY (Exact name of registrant as specified in its charter) AXP 8-K 2/29/2016 Section 1: 8-K (FORM 8-K OF AMERICAN EXPRESS COMPANY) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of

More information

PACIFIC ETHANOL, INC. (Exact name of registrant as specified in its charter)

PACIFIC ETHANOL, INC. (Exact name of registrant as specified in its charter) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported)

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: January 13, 2012 Date

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

APPLE HOSPITALITY REIT, INC. (Exact name of registrant as specified in its charter)

APPLE HOSPITALITY REIT, INC. (Exact name of registrant as specified in its charter) APLE 8-K 4/23/2015 Section 1: 8-K (8-K) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event

More information

Form 8-K. Texas Competitive Electric Holdings CO LLC - TXU. Filed: October 05, 2007 (period: October 05, 2007)

Form 8-K. Texas Competitive Electric Holdings CO LLC - TXU. Filed: October 05, 2007 (period: October 05, 2007) Form 8-K Texas Competitive Electric Holdings CO LLC - TXU Filed: October 05, 2007 (period: October 05, 2007) Report of unscheduled material events or corporate changes. Table of Contents ITEM 8.01. ITEM

More information

EVERYDAY HEALTH, INC.

EVERYDAY HEALTH, INC. EVERYDAY HEALTH, INC. FORM 8-K (Current report filing) Filed 05/11/15 for the Period Ending 05/11/15 Address 345 HUDSON STREET 16TH FLOOR NEW YORK, NY 10014 Telephone 718-797-0722 CIK 0001358483 Symbol

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION. Washington, D.C. 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION. Washington, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event

More information

ONCOTHYREON INC. FORM 424B3. (Prospectus filed pursuant to Rule 424(b)(3)) Filed 12/22/10

ONCOTHYREON INC. FORM 424B3. (Prospectus filed pursuant to Rule 424(b)(3)) Filed 12/22/10 ONCOTHYREON INC. FORM 424B3 (Prospectus filed pursuant to Rule 424(b)(3)) Filed 12/22/10 Address 2601 FOURTH AVENUE SUITE 500 SEATTLE, WA 98121 Telephone (206) 801-2100 CIK 0001412067 Symbol ONTY SIC Code

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

SANTANDER DRIVE AUTO RECEIVABLES LLC

SANTANDER DRIVE AUTO RECEIVABLES LLC SANTANDER DRIVE AUTO RECEIVABLES LLC FORM 8-K (Current report filing) Filed 03/12/13 for the Period Ending 03/06/13 Address 8585 NORTH STEMMONS FREEWAY SUITE 1100-N DALLAS, TX 75247 Telephone 214-237-3530

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A AMENDMENT #1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A AMENDMENT #1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A AMENDMENT #1 CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date

More information

Ladenburg Thalmann Financial Services Inc.

Ladenburg Thalmann Financial Services Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

General Cable Corporation (Exact name of registrant as specified in its charter)

General Cable Corporation (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest

More information

FEDERAL DEPOSIT INSURANCE CORPORATION Washington, D.C. 20429 FORM 8-K. Summit State Bank (Exact name of registrant as specified in its charter)

FEDERAL DEPOSIT INSURANCE CORPORATION Washington, D.C. 20429 FORM 8-K. Summit State Bank (Exact name of registrant as specified in its charter) FEDERAL DEPOSIT INSURANCE CORPORATION Washington, D.C. 20429 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported):

More information

Illumina, Inc. (Exact name of registrant as specified in its charter)

Illumina, Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

Cellular Biomedicine Group, Inc.

Cellular Biomedicine Group, Inc. SECURITIES & EXCHANGE COMMISSION EDGAR FILING Cellular Biomedicine Group, Inc. Form: 8-K Date Filed: 2014-07-31 Corporate Issuer CIK: 1378624 Symbol: CBMG SIC Code: 2836 Copyright 2014, Issuer Direct Corporation.

More information

QUALCOMM INC/DE FORM 8-K. (Current report filing) Filed 09/30/15 for the Period Ending 09/28/15

QUALCOMM INC/DE FORM 8-K. (Current report filing) Filed 09/30/15 for the Period Ending 09/28/15 QUALCOMM INC/DE FORM 8-K (Current report filing) Filed 09/30/15 for the Period Ending 09/28/15 Address 5775 MOREHOUSE DR SAN DIEGO, CA 92121 Telephone 8585871121 CIK 0000804328 Symbol QCOM SIC Code 3663

More information

Cord Blood America, Inc.

Cord Blood America, Inc. SECURITIES & EXCHANGE COMMISSION EDGAR FILING Cord Blood America, Inc. Form: 8-K Date Filed: 2013-05-20 Corporate Issuer CIK: 1289496 Symbol: CBAI SIC Code: 8071 Fiscal Year End: 12/31 Copyright 2014,

More information

ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter)

ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

SYNACOR, INC. FORM 8-K. (Current report filing) Filed 08/03/16 for the Period Ending 08/03/16

SYNACOR, INC. FORM 8-K. (Current report filing) Filed 08/03/16 for the Period Ending 08/03/16 SYNACOR, INC. FORM 8-K (Current report filing) Filed 08/03/16 for the Period Ending 08/03/16 Address 40 LARIVIERE DRIVE SUITE 300 BUFFALO, NY 14202 Telephone 716-853-1362 CIK 0001408278 Symbol SYNC SIC

More information

BRIDGEPOINT EDUCATION INC

BRIDGEPOINT EDUCATION INC BRIDGEPOINT EDUCATION INC FORM 8-K (Current report filing) Filed 11/12/13 for the Period Ending 11/08/13 Address 13500 EVENING CREEK DR. #600 SAN DIEGO, CA 92128 Telephone 858-668-2586 CIK 0001305323 Symbol

More information

CNA FINANCIAL CORPORATION

CNA FINANCIAL CORPORATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

CALGON CARBON CORP FORM 8-K. (Current report filing) Filed 04/04/11 for the Period Ending 03/31/11

CALGON CARBON CORP FORM 8-K. (Current report filing) Filed 04/04/11 for the Period Ending 03/31/11 CALGON CARBON CORP FORM 8-K (Current report filing) Filed 04/04/11 for the Period Ending 03/31/11 Address 3000 GSK DRIVE MOON TOWNSHIP, PA 15018 Telephone 4127876700 CIK 0000812701 Symbol CCC SIC Code

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event

More information

FORD MOTOR CREDIT COMPANY LLC

FORD MOTOR CREDIT COMPANY LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 1, 2011 (Date

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

STURM, RUGER & COMPANY, INC. (Exact Name of Registrant as Specified in its Charter)

STURM, RUGER & COMPANY, INC. (Exact Name of Registrant as Specified in its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

XENOPORT INC FORM 8-K. (Current report filing) Filed 05/08/14 for the Period Ending 05/08/14

XENOPORT INC FORM 8-K. (Current report filing) Filed 05/08/14 for the Period Ending 05/08/14 XENOPORT INC FORM 8-K (Current report filing) Filed 05/08/14 for the Period Ending 05/08/14 Address 3410 CENTRAL EXPRESSWAY SANTA CLARA, CA 95051 Telephone 4086167200 CIK 0001130591 Symbol XNPT SIC Code

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

Cord Blood America, Inc.

Cord Blood America, Inc. SECURITIES & EXCHANGE COMMISSION EDGAR FILING Cord Blood America, Inc. Form: 8-K Date Filed: 2008-01-31 Corporate Issuer CIK: 1289496 Symbol: CBAI SIC Code: 8071 Fiscal Year End: 12/31 Copyright 2014,

More information

GULFPORT ENERGY CORPORATION

GULFPORT ENERGY CORPORATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities exchange act of 1934 Date of report (Date of earliest event

More information

FXCM INC. FORM 8-K. (Current report filing) Filed 09/09/15 for the Period Ending 09/03/15

FXCM INC. FORM 8-K. (Current report filing) Filed 09/09/15 for the Period Ending 09/03/15 FXCM INC. FORM 8-K (Current report filing) Filed 09/09/15 for the Period Ending 09/03/15 Address 55 WATER ST. FL 50 NEW YORK, NY 10041 Telephone 6464322241 CIK 0001499912 Symbol FXCM SIC Code 6200 - Security

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event

More information

FEDERATED NATIONAL HOLDING COMPANY (Exact name of registrant as specified in its charter)

FEDERATED NATIONAL HOLDING COMPANY (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 15, 2015 (Date

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event

More information

GSV CAPITAL CORP. FORM 8-K. (Current report filing) Filed 04/28/15 for the Period Ending 04/28/15

GSV CAPITAL CORP. FORM 8-K. (Current report filing) Filed 04/28/15 for the Period Ending 04/28/15 GSV CAPITAL CORP. FORM 8-K (Current report filing) Filed 04/28/15 for the Period Ending 04/28/15 Address 2925 WOODSIDE ROAD WOODSIDE, CA 94062 Telephone (650) 235-4777 CIK 0001509470 Symbol GSVC Industry

More information

THE GOLDMAN SACHS GROUP, INC. (Exact name of registrant as specified in its charter)

THE GOLDMAN SACHS GROUP, INC. (Exact name of registrant as specified in its charter) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

SORRENTO THERAPEUTICS, INC.

SORRENTO THERAPEUTICS, INC. ˆ200F@WVSVmdG1Yng+Š 200F@WVSVmdG1Yng+ AZ0151AC599817 11.3.10 SWRvelaj0nb 31-Jul-2013 16:51 EST 577580 TX 1 3* UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant

More information